uniQure N.V ($QURE) Insider Trading & Smart Money Activity
uniQure N.V. ($QURE) has 23 insider trades, 2 13F position changes and 5 analyst ratings on file. In the last 12 months on the open market, no insider bought and 11 insiders sold ($12.41M), net -$12.41M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 11
- Net insider $ (12 mo)
- -$12.41M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 5
QURE insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 15 · $12.41M | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All QURE insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | HC Wainwright | Reiterates to buy | PT $80 | -12.7% | -15.4% | Read | |||||
| Insider | Walid Abi-SaabChief Medical Officer | Sell (Open-market sale) | 1.43K sh | $67.20K | -12.9% | -19.6% | Read | ||||
| Analyst | Mizuho | Reiterates to buy | PT $68 | -14.8% | -22.2% | Read | |||||
| Insider | Matthew KapustaCEO, Managing Director | Sell (Open-market sale) 10b5-1 | 28.72K sh | $1.44M | -14.8% | -22.2% | — | ||||
| Insider | Matthew KapustaCEO, Managing Director | Buy (Option exercise) | 28.72K sh | $910.58K | -14.8% | -22.2% | — | ||||
| Insider | Matthew KapustaCEO, Managing Director | Sell (Open-market sale) 10b5-1 | 6.70K sh | $334.80K | -7.5% | -20.2% | Read | ||||
| Insider | Matthew KapustaCEO, Managing Director | Buy (Option exercise) | 4.13K sh | $130.90K | -7.5% | -20.2% | Read | ||||
| Analyst | RBC Capital | Reiterates to buy | PT $65 | +6.1% | -14.2% | Read | |||||
| Analyst | Leerink Partners | Reiterates to buy | PT $70 | +6.1% | -14.2% | Read | |||||
| Insider | Matthew KapustaCEO, Managing Director | Sell (Open-market sale) 10b5-1 | 41.67K sh | $2.08M | +6.1% | -14.2% | Read | ||||
| Insider | Matthew KapustaCEO, Managing Director | Buy (Option exercise) | 4.66K sh | $147.64K | +6.1% | -14.2% | Read | ||||
| Analyst | Barclays | Raises to buy | PT $65 | +6.1% | -14.2% | Read | |||||
| Insider | Jack Kaye | Sell (Open-market sale) 10b5-1 | 5.29K sh | $225.41K | +1.4% | -16.4% | Read | ||||
| Insider | Jack Kaye | Buy (Option exercise) | 5.29K sh | $167.90K | +1.4% | -16.4% | Read | ||||
| Insider | Matthew KapustaCEO, Managing Director | Sell (Open-market sale) 10b5-1 | 164.43K sh | $7.29M | +1.4% | -16.4% | Read | ||||
| Insider | Matthew KapustaCEO, Managing Director | Buy (Option exercise) | 62.58K sh | $1.21M | +1.4% | -16.4% | Read | ||||
| Insider | Madhavan Balachandran | Sell (Option exercise) | 11.69K sh | +1.4% | -16.4% | Read | |||||
| Insider | Madhavan Balachandran | Buy (Option exercise) | 11.69K sh | $291.81K | +1.4% | -16.4% | Read | ||||
| Insider | Jeannette PottsChief Legal Officer | Sell (Open-market sale) | 5.24K sh | $144.91K | +59.3% | +47.1% | Read | ||||
| Insider | Madhavan Balachandran | Sell (Option exercise) | 10K sh | +59.3% | +47.1% | Read | |||||
| Insider | Jeremy Springhorn | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| Insider | Leonard Post | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| Insider | Kylie O'KeefeChief Customer & Strat Officer | Sell (Open-market sale) | 15.94K sh | $431.23K | +72.6% | +53.2% | — | ||||
| Insider | David Meek | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| Insider | Jack Kaye | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| Insider | Jacques Rachelle Suzanne | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| Insider | Robert Gut | Sell (Open-market sale) 10b5-1 | 2.73K sh | $73.77K | +72.6% | +53.2% | — | ||||
| Insider | Madhavan Balachandran | Sell (Open-market sale) | 1.99K sh | $53.93K | +72.6% | +53.2% | — | ||||
| 13F | Rtw Investments | Reduced | -1.13M sh | $120.07M | -10.6% | +3.0% | Read | ||||
| 13F | Avoro Capital Advisors | Reduced | -190.41K sh | $276.67M | -10.6% | +3.0% | Read |
1W / 1M / 6M = how QURE moved from the trade or filing date.
Insider trading in QURE: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Walid Abi-Saab | Chief Medical Officer | 1 | -$67.20K | Jun 26, 2026 | |
| Matthew Kapusta | CEO, Managing Director | 8 | -$11.14M | Jun 25, 2026 | |
| Madhavan Balachandran | 4 | -$53.93K | Jun 17, 2026 | ||
| Jack Kaye | 3 | -$279.34K | Jun 17, 2026 | ||
| Jeannette Potts | Chief Legal Officer | 1 | -$144.91K | Jun 15, 2026 | |
| Jeremy Springhorn | 1 | -$53.93K | Jun 11, 2026 | ||
| Leonard Post | 1 | -$53.93K | Jun 11, 2026 | ||
| Kylie O'Keefe | Chief Customer & Strat Officer | 1 | -$431.23K | Jun 11, 2026 | |
| David Meek | 1 | -$53.93K | Jun 11, 2026 | ||
| Jacques Rachelle Suzanne | 1 | -$53.93K | Jun 11, 2026 | ||
| Robert Gut | 1 | -$73.77K | Jun 11, 2026 |
Institutions moving QURE (13F)
Analyst ratings on QURE
Frequently asked questions
Are QURE insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 11 insiders made 15 open-market sales worth $12.41M, a net -$12.41M.
What is the latest insider trade in QURE?
Walid Abi-Saab, Chief Medical Officer filed a sell (open-market sale) of 1.43K sh worth $67.20K on Jun 26, 2026.
Which institutions changed their QURE positions?
Recent 13F filers moving the stock include Rtw Investments and Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.